We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

GSK and Theravance Announce Initial Outcomes From Pivotal Phase III Studies for Once-Daily Relovair™* in COPD and Asthma

News   Jan 09, 2012

 
GSK and Theravance Announce Initial Outcomes From Pivotal Phase III Studies for Once-Daily Relovair™* in COPD and Asthma
 
 
 

RELATED ARTICLES

First Generic Version of EpiPen Is Approved

News

The U.S. Food and Drug Administration has approved the first generic version of EpiPen and EpiPen Jr (epinephrine) auto-injector for the emergency treatment of allergic reactions, including those that are life-threatening (anaphylaxis), in adults and pediatric patients who weigh more than 33 pounds.

READ MORE

41% of Parents May Seek New Provider Because of Unvaccinated Children at Their Doctor’s Office

News

Four in 10 parents say they are very or somewhat likely to move their child to a different provider if their doctor sees families who refuse all childhood vaccines, according to a new national poll.

READ MORE

Team Design Drug Molecule to Improve Heart Attack Recovery

News

A new molecule has been developed that could help preserve heart tissue during – and even after – a heart attack.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE